Page 2469 - Williams Hematology ( PDFDrive )

2440 Index Index 2441

Hemangioblasts, 257, 258 marrow endothelial cells in, 56–57 aplastic anemia, 522–523
Hemangioendothelioma, Kaposi-like, 2014 osteoblasts in, 60 Burkitt lymphoma, 1676
Hemangiomas, 2209–2210 osteoclasts in, 60–61 Chédiak-Higashi syndrome, 1020
Hemarthroses, 1988, 2116–2117, 2117f, sites of, 54–55, 54f chronic granulomatous disease, 1032
2118f, 2119f, 2122t, 2129 stem cell model of, 354–355 chronic lymphocytic leukemia, 1539
Hematemesis, 5, 1987 yolk sac, 99–100 chronic myelogenous leukemia,
Hematochezia, history of, 5 Hematopoietic cell phosphatase (HCP, 1460–1461, 1466–1467
Hematocrit (Hct), 488, 488f SHP1), 253, 485, 486f, 1163 diffuse large B-cell lymphoma,
anemia and, 505f Hematopoietic cell transplantation (HCT), 1631–1632
blood viscosity and, 506, 508f 353–374 familial hemophagocytic
in chronic renal disease and, 550f allogeneic, 358–359 lymphohistiocytosis, 1228
hypervolemia and, 506, 510f cytomegalovirus infection following, follicular lymphoma, 1648, 1648f
measurement, 13–14 409–410 Hodgkin lymphoma, 1248, 1616
neonatal, 102–103 dendritic cell role in, 310 inherited platelet disorders, 2062
reference ranges, 18t graft failure after, 367 inherited pure red cell aplasia, 540
total-body, 489 graft-versus-tumor effects, 359 juvenile myelomonocytic leukemia,
Hematologic consultation, 3, 4t nonmyeloablative, 1400, 1408 1471
advice to referring physicians, 49 preparative regimens, 359–360 mantle cell lymphoma, 1656, 1656f,
for anemia, 42 relapse after, 373 1658t
for bleeding, 46 for tolerance of solid-organ allografts, myelodysplastic syndromes, 1361–1362
for erythrocytosis/polycythemia, 44–45 373–374 myeloma, 1750–1751, 1755–1756
for immature cells on the blood film, assays, 259–260 Omenn syndrome, 1219
47–48 autologous, 358 paroxysmal nocturnal hemoglobinuria,
for leukocytosis, 43–44 graft failure after, 367 579–580, 579t
for leukopenia, 41–42 graft purging strategies, 358 peripheral T-cell lymphoma, 1696, 1697
for lymphadenopathy, 48 preparative regimens, 359–360 polycythemia vera, 1301
for monoclonal gammopathy, 48–49 relapse after, 373 primary myelofibrosis, 1330–1331
for pancytopenia, 43 secondary acute myelogenous leukemia severe combined immunodeficiency,
in pregnancy, 45–46 and, 1407 1219
for splenomegaly, 48 tumor contamination in, 358 sickle cell disease, 775
for thrombocytopenia, 42–43 candidate evaluation and selection, 361– systemic mastocytosis, 977
for thrombocytosis, 45 362, 361t thalassemias, 753–754
for thrombosis, 46–47 complications, 366–373, 367t Waldenström macroglobulinemia, 1796
Hematomas, 2117–2118, 2119f, 2122t bleeding, 2382 Wiskott-Aldrich syndrome, 1225
Hematon, 263 cytomegalovirus infection, 1267–1268, preparative regimens, 359–361
Hematopoiesis 2373–2374 chemotherapy-only, 360
in acute myelogenous leukemia, 1281f graft failure, 366–367 reduced-intensity, 360–361, 367
aging and, 132–134 graft-versus-host disease. See Graft- total-body irradiation, 359–360
controversies in, 267–268 versus-host disease (GVHD) results, 363–366, 365f. See also specific
developmental biology of, 257–259 infection. See Infection, in diseases
dysfunction of, in primary myelofibrosis, immunocompromised host sources of stem cells for, 355–358
1321–1322 regimen-related organ toxicities, alternative donors, 356–357
extramedullary, 1323 367–368 blood, 355–356
fetal, 99–102, 100f, 102f, 1149–1150 relapsed malignancy, 373 comparison of, 358
hepatic, 100–101 thrombotic microangiopathy, 2262 HLA-haploidentical donors, 357–358
interplay of clonal and polyclonal, 1284 transfusion-related, 2373–2374, 2373t marrow, 355
marrow, fetal, 101 future directions, 373–374 umbilical cord blood, 357
murine, 1149 history, 353–354, 354t stem cell model of hematopoiesis and,
natural killer cells and, 1191–1192 indications, 362–363 354–355
neonatal, 102–109 acute lymphoblastic leukemia, syngeneic, 359
overview, 257, 258f, 1282, 1282f 1517–1518 trafficking/homing of hematopoietic stem
regulation acute myelogenous leukemia, cells and, 355
adipocytes in, 59 1399–1400, 1402, 1407 transfusion support, 2372–2374, 2373t
adventitial reticular cells in, 57–59, 58f acute promyelocytic leukemia, 1406 Hematopoietic cytokine receptor family,
bone cells in, 59–60 adult T-cell leukemia/lymphoma, 1701 247–249
macrophages in, 61, 1071 AL amyloidosis, 1780 Hematopoietic dysplasia, 1277, 1343

Kaushansky_index_p2393-2506.indd 2440 9/21/15 3:22 PM